Minerva Neurosciences, Inc (NERV) is a publicly traded Healthcare sector company. As of May 21, 2026, NERV trades at $4.67 with a market cap of $220.83M and a P/E ratio of -0.14. NERV moved +15.71% today. Year to date, NERV is +21.20%; over the trailing twelve months it is +264.49%. Its 52-week range spans $1.15 to $12.46. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces NERV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
2 analysts cover NERV: 0 strong buy, 1 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $10.50.
| Metric | Value |
|---|---|
| Price | $4.67 |
| Market Cap | $220.83M |
| P/E Ratio | -0.14 |
| EPS | $-34.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.46 |
| 52-Week Low | $1.15 |
| Volume | 39 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-293.42M |
| Gross Margin | 0.00% |
2 analysts cover NERV: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.